trending Market Intelligence /marketintelligence/en/news-insights/trending/x5R1UanlyN3cSx36Br-Wbg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers, Pfizer's blood clot drug shows favorable safety in phase 4 trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bristol-Myers, Pfizer's blood clot drug shows favorable safety in phase 4 trial

Bristol-Myers Squibb Co. and Pfizer Inc. said their blood thinner Eliquis showed favorable safety results in certain heart disease patients in a phase 4 trial.

The phase 4 study, called Augustus, evaluated the safety of Eliquis compared to drugs known as vitamin K antagonists in patients with non-valvular atrial fibrillation, or NVAF. The patients have recent acute coronary syndrome, or ACS, are undergoing percutaneous coronary intervention or both.

NVAF is a disorder characterized by irregular heart rhythm not caused by a fault with the heart's valves. The condition can cause blood clots leading to a stroke — a scenario that patients could prevent with anti-blood clotting therapies such as Eliquis or vitamin K antagonists.

Under the 4,614-patient Augustus study, significantly fewer patients who were given Eliquis showed major or clinically relevant non-major bleeding after six months compared to those treated with a vitamin K antagonist. Patients evaluated in the trial were receiving a P2Y12 inhibitor with or without aspirin.

The results of the study were presented March 17 at the American College of Cardiology's 68th Annual Scientific Session.

ACS is an umbrella term for situations where blood supply to the heart muscle is blocked, such as a heart attack or angina. Percutaneous coronary intervention is a procedure where a thin tube called a catheter is used to place a structure, or stent, to open up blood vessels in the heart that have been narrowed due to plaque buildup.

New York's Bristol-Myers Squibb and Pfizer teamed up to develop and commercialize Eliquis, or apixaban, in a collaboration they entered in 2007. The therapy is approved for multiple indications in the U.S.